Suzhou Zelgen Biopharmaceuticals (ZLGN HK): Synthetic Expert Call Transcript (15 Aug 2026)
H1 2026 Paper Profitability is Unreconstructedly Transitory: While Suzhou Zelgen Biopharmaceuticals reported its first-ever half-year net profit...
97 Views
IPO Databook: Suzhou Zelgen Biopharmaceuticals (HK) - Aug 2026
Suzhou Zelgen Biopharmaceuticals is an integrated biopharmaceutical company focused on oncology, autoimmune diseases, and hemostasis/hematology,...
103 Views
No more insights